GlassScriptPhysician profile
Takela N Anderson
NPI 1023342144
$10,102.48
in general payments reported to CMS, 2019-2025
50 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,227 · 2022: $2,051 · 2023: $1,575 · 2024: $2,073 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,715 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,715.27 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.11 | 2021-2025 | |
| Novo Nordisk INC | $1,145.06 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,004.43 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Neurocrine Biosciences, INC. | $873.04 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $665.89 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $612.74 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $448.39 | 2021-2025 | |
| Pfizer INC. | $427.57 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.13 | 2021-2025 | Caplyta |
| Amgen INC. | $274.27 | 2021-2024 | Otezla, Repatha |
| Lundbeck LLC | $271.36 | 2022-2025 | Abilify Maintena, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.64 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $237.18 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $213.88 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $191.36 | 2024-2025 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Takela Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.